Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Endometriosis Treatment Pipeline Review H2 2016

Friday, October 14, 2016 3:15
% of readers think this story is Fact. Add your two cents.

(Before It's News)


‘Endometriosis – Pipeline Review, H2 2016’, provides an overview of the Endometriosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Endometriosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects.

Request a sample report @

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


- The report provides a snapshot of the global therapeutic landscape of Endometriosis 
- The report reviews pipeline therapeutics for Endometriosis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Endometriosis therapeutics and enlists all their major and minor projects 
- The report assesses Endometriosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Endometriosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Endometriosis 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Endometriosis pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @

Key points in table of content

Table of Contents 2 
List of Tables 8 
List of Figures 9 
Introduction 10 
Global Markets Direct Report Coverage 10 
Endometriosis Overview 11 
Therapeutics Development 12 
Pipeline Products for Endometriosis – Overview 12 
Pipeline Products for Endometriosis – Comparative Analysis 13 
Endometriosis – Therapeutics under Development by Companies 14 
Endometriosis – Therapeutics under Investigation by Universities/Institutes 16 
Endometriosis – Pipeline Products Glance 17 
Late Stage Products 17 
Clinical Stage Products 18 
Early Stage Products 19 
Unknown Stage Products 20 
Endometriosis – Products under Development by Companies 21 
Endometriosis – Products under Investigation by Universities/Institutes 24 
Endometriosis – Companies Involved in Therapeutics Development 25 
AbbVie Inc 25 
Addex Therapeutics Ltd 26 
APAvadis Biotechnologies Srl 27 
Astellas Pharma Inc. 28 
Bayer AG 29 
Dongkook Pharmaceutical Co., Ltd. 30 
ElexoPharm GmbH 31 
EndoCeutics, Inc. 32 
Enteris BioPharma, Inc. 33 
Euroscreen S.A. 34 
Evotec AG 35 
Forendo Pharma Limited 36 
GlaxoSmithKline Plc 37 
Kissei Pharmaceutical Co., Ltd. 38 
Lipicard Technologies Limited 39 
Luye Pharma Group Ltd. 40 
Nippon Shinyaku Co., Ltd. 41 
Orphagen Pharmaceuticals, Inc. 42 
Philogen S.p.A. 43 
Repros Therapeutics Inc. 44 
SK Chemicals Co., Ltd. 45 
Takeda Pharmaceutical Company Limited 46 
ValiRx Plc 47 
Endometriosis – Therapeutics Assessment 48 
Assessment by Monotherapy Products 48 
Assessment by Combination Products 49 
Assessment by Target 50 
Assessment by Mechanism of Action 53 
Assessment by Route of Administration 56 
Assessment by Molecule Type 58 
Drug Profiles 60 
acolbifene hydrochloride + GnRH Agonist + prasterone – Drug Profile 60 
Product Description 60 
Mechanism Of Action 60 
R&D Progress 60 
ASP-1707 – Drug Profile 61 
Product Description 61 
Mechanism Of Action 61 
R&D Progress 61 
BAY-1128688 – Drug Profile 62 
Product Description 62 
Mechanism Of Action 62 
R&D Progress 62 
bentamapimod – Drug Profile 63 
Product Description 63 
Mechanism Of Action 63 
R&D Progress 63 
Drug to Inhibit C-Jun for Endometriosis – Drug Profile 64 
Product Description 64 
Mechanism Of Action 64 
R&D Progress 64 
Drugs for Endometriosis – Drug Profile 65 
Product Description 65 
Mechanism Of Action 65 
R&D Progress 65 
Drugs for Endometriosis and Uterine Fibroids – Drug Profile 66 
Product Description 66 
Mechanism Of Action 66 
R&D Progress 66 
elagolix sodium – Drug Profile 67 
Product Description 67 
Mechanism Of Action 67 
R&D Progress 67 
epelsiban besylate – Drug Profile 71 
Product Description 71 
Mechanism Of Action 71 
R&D Progress 71 
ESN-364 – Drug Profile 73 
Product Description 73 
Mechanism Of Action 73 
R&D Progress 73 
EVE-104 – Drug Profile 75 
Product Description 75 
Mechanism Of Action 75 
R&D Progress 75 
FP-5677 – Drug Profile 76 
Product Description 76 
Mechanism Of Action 76 
R&D Progress 76 
goserelin biosimilar – Drug Profile 77 
Product Description 77 
Mechanism Of Action 77 
R&D Progress 77 
goserelin ER – Drug Profile 78 
Product Description 78 
Mechanism Of Action 78 
R&D Progress 78 
KLH-2109 – Drug Profile 79 
Product Description 79 
Mechanism Of Action 79 
R&D Progress 79 
leuprolide acetate – Drug Profile 80 
Product Description 80 
Mechanism Of Action 80 
R&D Progress 80 
LT-6121 – Drug Profile 81 
Product Description 81 
Mechanism Of Action 81 
R&D Progress 81 
MIA-602 – Drug Profile 82 
Product Description 82 
Mechanism Of Action 82 
R&D Progress 82 
Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis – Drug Profile 83 
Product Description 83 
Mechanism Of Action 83 
R&D Progress 83 
NS-580 – Drug Profile 84 
Product Description 84 
Mechanism Of Action 84 
R&D Progress 84 
Peptides for Endometriosis and Hepatic Tumor – Drug Profile 85 
Product Description 85 
Mechanism Of Action 85 
R&D Progress 85 
Peptides to Inhibit Aminopeptidase A for Endometriosis and Hepatic (Liver) Tumor – Drug Profile 86 
Product Description 86 
Mechanism Of Action 86 
R&D Progress 86 
PGL-2001 – Drug Profile 87 
Product Description 87 
Mechanism Of Action 87 
R&D Progress 87 
Recombinant Protein for Endometriosis and Ovarian Hyperstimulation Syndrome – Drug Profile 88 
Product Description 88 
Mechanism Of Action 88 
R&D Progress 88 
relugolix – Drug Profile 89 
Product Description 89 
Mechanism Of Action 89 
R&D Progress 89 
SKI-2670 – Drug Profile 91 
Product Description 91 
Mechanism Of Action 91 
R&D Progress 91 
Small Molecule to Antagonize FSH Receptor for Women’s Health – Drug Profile 92 
Product Description 92 
Mechanism Of Action 92 
R&D Progress 92 
Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology – Drug Profile 93 
Product Description 93 
Mechanism Of Action 93 
R&D Progress 93 
Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis – Drug Profile 94 
Product Description 94 
Mechanism Of Action 94 
R&D Progress 94 
Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing’s Disease – Drug Profile 95 
Product Description 95 
Mechanism Of Action 95 
R&D Progress 95 
Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis – Drug Profile 96 
Product Description 96 
Mechanism Of Action 96 
R&D Progress 96 
Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers – Drug Profile 97 
Product Description 97 
Mechanism Of Action 97 
R&D Progress 97 
Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis – Drug Profile 98 
Product Description 98 
Mechanism Of Action 98 
R&D Progress 98 
SR-16234 – Drug Profile 99 
Product Description 99 
Mechanism Of Action 99 
R&D Progress 99 
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology – Drug Profile 100 
Product Description 100 
Mechanism Of Action 100 
R&D Progress 100 
telapristone acetate – Drug Profile 101 
Product Description 101 
Mechanism Of Action 101 
R&D Progress 101 
Tetravil – Drug Profile 109 
Product Description 109 
Mechanism Of Action 109 
R&D Progress 109 
triptorelin biosimilar – Drug Profile 111 
Product Description 111 
Mechanism Of Action 111 
R&D Progress 111 
VAL-201 – Drug Profile 112 
Product Description 112 
Mechanism Of Action 112 
R&D Progress 112 
vilaprisan – Drug Profile 116 
Product Description 116 
Mechanism Of Action 116 
R&D Progress 116 
VPE-001 – Drug Profile 117 
Product Description 117 
Mechanism Of Action 117 
R&D Progress 117 
VPEA-004 – Drug Profile 118 
Product Description 118 
Mechanism Of Action 118 
R&D Progress 118 
Endometriosis – Dormant Projects 119 
Endometriosis – Discontinued Products 121 
Endometriosis – Product Development Milestones 122 
Featured News & Press Releases 122 
Aug 05, 2016: Evotec Achieves Clinical Development Milestone as Part of Its Multi-Target Alliance with Bayer in Endometriosis 122 
Jul 06, 2016: ObsEva Receives Clearance from US FDA to Initiate Phase 2b Study EDELWEISS with OBE2109, a Potentially Best-in-Class Oral GnRH Antagonist, for the Treatment of Endometriosis 122 
Mar 31, 2016: ValiRx is exhibiting and presenting at the prestigious AACR 123 
Feb 10, 2016: AbbVie Announces Positive Top-Line Results From Second Phase 3 Study Investigating Elagolix in Patients with Endometriosis 123 
Dec 21, 2015: Repros Updates Proellex Program 124 
Mar 24, 2015: Bayer to present new preclinical, early clinical and epidemiological data on Vilaprisan at 62nd Annual Scientific Meeting, March 25-28, 2015, in San Francisco, CA 124 
Feb 26, 2015: New Endometriosis Patent Grant for ValiRx 125 
Jan 15, 2015: Clinical Trial and Development Update on VAL201 for oncology indications 126 
Jan 08, 2015: Abbvie Announces Positive Top-Line Results From Phase 3 Study Of Investigational Medicine Elagolix In Patients With Endometriosis 126 
Jun 20, 2014: Euroscreen ESN364 drug candidate presented at the ICE/ENDO Meeting 127 
Apr 01, 2014: ValiRx Provides Updated On Anti-cancer Therapeutic VAL201 128 
Mar 13, 2014: New drug candidate showed efficacy in human endometriosis samples 128 
Dec 18, 2013: Euroscreen Initiates Phase I Clinical Trial For ESN364 128 
Oct 03, 2013: ValiRx Files Phase IB/dose escalation study for VAL201 129 
Aug 29, 2013: Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis 129 
Appendix 131 
Methodology 131 
Coverage 131 
Secondary Research 131 
Primary Research 131 
Expert Panel Validation 131 
Contact Us 131 
Disclaimer 132

Get this report @


Contact US:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.